Skip to content
OpenCapital
Get started

BioMarin Pharmaceuticals BMRN Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.43B+74.4%
Biogen logo
BiogenBIIB
——
Globus Medical logo
Globus MedicalGMED
——
Cytokinetics logo
CytokineticsCYTK
——
Roivant Sciences logo
Roivant SciencesROIV
——

Other financials

Income statement

See full
Revenue$766.2M+2.8%
Gross profit$571.2M-3.8%
Operating income$129.6M-42.1%
Net income$105.5M-43.2%
EPS (diluted)$0.54-43.2%

Balance sheet

See full
Cash & equivalents$3.1B+193%
Total debt$1.4B+138%
Total equity$6.2B+7.2%
Total assets$8.6B+20.2%

Cash flow

See full
Operating cash flow$220.7M+26.5%
CapEx$20.9M+24.8%
Free cash flow$199.7M+26.7%

Valuation

See full
Market cap$10.57B-19.4%
Enterprise value$8.93B-29.3%
P/E21.1×-22.7×
P/S3.3×-1.2×

Profitability

See full
Gross margin76.5%-2.9pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin23.7%+2.5pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.2×+0.1×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
BioMarin Pharmaceuticals (BMRN) reported cash provided by (used in) operating activity, including discontinued operation of $220.65M in Q1 2026.
How has BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation increased by 26.5% year-over-year, from $174.39M to $220.65M.
What is the long-term trend for BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's cash provided by (used in) operating activity, including discontinued operation has grown at a 28.4% compound annual growth rate (CAGR), from $304.54M to $827.99M.